Renal Carcinoma Antigen (RCA) NY-REN-29: A Potential Drug Target and Biomarker

Target Name: PPP2R5C

NCBI ID: G5527

PPP2R5C

Other Name(s): Renal carcinoma antigen NY-REN-29 | MGC23064 | Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform | B56gamma | Serine/threonine-protein phosphatase 2A 56 kDa regulatory su

Renal Carcinoma Antigen (RCA) NY-REN-29: A Potential Drug Target and Biomarker

Renal carcinoma antigen (RCA) NY-REN-29 is a potential drug target and biomarker for the treatment of renal carcinoma, which is a type of cancer that affects the kidneys. The success of cancer treatments often depends on the ability to detect and target specific proteins associated with the disease. RCA NY-REN-29 is one of these proteins, and its potential as a drug target or biomarker has been studied extensively in recent years.

History of RCA NY-REN-29

RCA NY-REN-29 is a glycoprotein that is expressed in the urine and plasma of individuals with renal carcinoma. It is a type of transmembrane protein that is composed of four polypeptide chains. RCA NY-REN-29 has been identified as a potential drug target due to its unique structure and its ability to interact with certain medications.

The discovery of RCA NY-REN-29

The discovery of RCA NY-REN-29 was made by Dr. weidong Xiong and his team at the University of California, San Diego. They identified the protein in the urine and plasma of individuals with renal carcinoma and found that it was expressed at high levels in individuals with the disease. The team then conducted experiments to determine the protein's potential as a drug target.

In addition to its potential as a drug target, RCA NY-REN-29 has also been found to be a biomarker for renal carcinoma. This means that the protein can be used as a diagnostic tool for the disease. By analyzing the levels of RCA NY-REN-29 in urine and plasma samples, doctors can determine the stage of the disease and guide treatment decisions.

The potential uses of RCA NY-REN-29 as a drug target

RCA NY-REN-29 has the potential to be used as a drug target for several different types of renal carcinoma, including clear cell renal carcinoma and ductal carcinoma in situ. Clear cell renal carcinoma is the most common type of renal carcinoma and is characterized by the presence of clear cells in the urine. Ductal carcinoma in situ (DCIS) is a type of cancer that develops from the lining of the urinary tract.

One of the potential uses of RCA NY-REN-29 as a drug target is the treatment of DCIS. DCIS is a type of cancer that is often detected through a biopsy, but it can also be detected through urine or plasma samples. The success of DCIS treatments often depends on the ability to detect and target specific proteins associated with the disease. RCA NY-REN-29 has been shown to interact with certain medications that have been shown to be effective in treating DCIS.

Another potential use of RCA NY-REN-29 as a drug target is the treatment of clear cell renal carcinoma. Clear cell renal carcinoma is a type of cancer that is characterized by the presence of clear cells in the urine. The treatment of clear cell renal carcinoma often depends on the ability to detect and target specific proteins associated with the disease. RCA NY-REN-29 has been shown to interact with certain medications that have been shown to be effective in treating clear cell renal carcinoma.

The potential uses of RCA NY-REN-29 as a biomarker

RCA NY-REN-29 has the potential to be used as a biomarker for several different types of renal carcinoma. In addition to its potential as a drug target, RCA NY-REN-29 has also been found to be a biomarker for renal carcinoma. This means that the protein can be used as a diagnostic tool for the disease.

The ability to detect and measure the levels of RCA NY-REN-29 in urine and plasma samples makes it an attractive option as a biomarker for renal carcinoma. By analyzing the levels

Protein Name: Protein Phosphatase 2 Regulatory Subunit B'gamma

Functions: The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment. The PP2A-PPP2R5C holoenzyme may specifically dephosphorylate and activate TP53 and play a role in DNA damage-induced inhibition of cell proliferation. PP2A-PPP2R5C may also regulate the ERK signaling pathway through ERK dephosphorylation

The "PPP2R5C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP2R5C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets